$0.84-0.8%Nov 13 close
The latest quarter (ended September 30, 2026) is from Stereotaxis’s earnings press release of November 10, 2026. It will be replaced by the official quarterly report (10-Q) once Stereotaxis files it.
Just reported
From Stereotaxis, Inc.'s results release of November 10, 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
$8.9M
+20% y/y
+16% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $8.9M | $7.5M | +19.57% |
| Profit | -$6.8M | -$6.5M | -5.18% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Stereotaxis, Inc. reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Our near-term priority is to drive forward two major business model transformations,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.
The company’s own description, as it appears at the foot of the release.
The quote, the company description and the latest quarter come from Stereotaxis’s earnings press release (an Item 2.02 8-K) filed November 10, 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Read the release on EDGAR Share prices are split- and dividend-adjusted.